Clinical Trial Update: An Open Label Study of FT218 in Subjects With Narcolepsy [Phase 3]

View source ↗

Summary

This open-label Phase 3 trial of FT218 in narcolepsy with cataplexy has completed, providing results on safety and efficacy in this population.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataplexy
• Narcolepsy

Drugs mentioned

• FT218 (sodium oxybate extended-release)

Snippet

Sponsor: Avadel | Conditions: Narcolepsy, Cataplexy | Phase 3 | Status: COMPLETED